The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions

Histopathology

Volumn 31, Issue 4, 1997, Pages 347-354

  Mustonen, M ^a   Raunio, H ^a   Paakko P ^a   Soini, Y ^a,b,c  

^a UNIVERSITY OF OULU   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Apoptosis; bcl 2; Breast; Carcinoma

Indexed keywords

AVIDIN; BIOTIN; MONOCLONAL ANTIBODY; PEROXIDASE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST HYPERPLASIA; BREAST TUMOR; CANCER GRADING; CANCER INVASION; CARCINOMA IN SITU; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0030768893     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1997.2710877.x     Document Type: Article

References (33)

1. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994; 124; 1-6.
2. Hockenbery DM. Bcl-2 in cancer. development and apoptosis. J. Cell Sci. 1994; 18; 51-55.
3. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73; 2013-2026.
4. White E. Life, death, and the pursuit of apoptosis. A review. Gene Dev. 1996; 19; 1-15.
5. Lu Q-L, Abel P, Foster CS, Lalani E-L. Bcl-2: role in epithelial differentiation and oncogenesis. Human Pathol 1996; 27; 102-110.
6. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls of cell death. Cell 1993; 74; 777-779.
7. McConkey DJ, Orrenius S. Signal transduction pathways to apoptosis. Trends Cell Biol. 1994; 4; 370-374.
8. Fisher DE. Apoptosis in cancer therapy: crossing the treshold. Cell 1994; 78; 539-542.
9. Törmänen U, Eerola A-K, Rainio P et al. Enhanced apoptosis predicts shortened survival In non-small cell lung carcinoma. Cancer Res. 1995; 55; 5595-5602.
10. Baretton GB, Diebold J, Christoforis G et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996; 77; 255-264.
11. Soini Y, Virkajärvi N, Lehto V-P et al. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br. J. Cancer 1996; 73; 1025-1030.
12. Vaux DL, Cory S, Adams TM. bcl-2 promotes the survival of haematopoetic cells and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335; 440-442.
13. Tsujimoto Y, Cossman J, Jaffe E et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228; 1440-1443.
14. Oltvai ZN, Nillman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog. bax. that accelerates programmed cell death. Cell 1993; 74; 609-619.
15. Yin X-M, Oltvai ZL, Korsmeyer SJ. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 1994; 369; 321-323.
16. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br. J. Cancer 1995; 72; 354-360.
17. Lipponen P, Pietiläinen T, Kosma V-M, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J. Pathol. 1995; 177; 49-55.
18. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am. J. Pathol. 1994; 145; 535-540.
19. Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am. J. Pathol. 1994; 145; 1191-1198.
20. World Health Organization. Histological Typing of Breast Tumours. 2nd edn. International Classification of Tumours. No. 2. Geneva: World Health Organization. 1981.
21. Tavassoli F. Pathology of the Breast. Norwalk, Connecticut: Appleton & Lange: 1992.
22. Bloom HJG. Richardson WW. Histological grading and prognosis in breast cancer. Br. J. Cancer 1957; 11; 359-377.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage Y4. Nature 1970; 227; 680-685.
24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979; 76; 4350-4354.
25. Eerola A-K. Törmänen U. Rainio P et al. Apoptosis in operated small cell lung carcinomas is inversely related to tumour necrosis and p53 immunoreactivity. J. Pathol. 1997; 181; 172-177.
26. Siziopikou KP, Prioleau JE, Harris JR. Schnitt SJ. bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 1996; 77; 499-506.
27. Bronner MP, Culin C. Reed JC et al. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am. J. Pathol. 1995; 146; 20-26.
28. Nakagawa K, Yamamura K, Maeda S et al. bcl-2 expression in epidermal keratinocytic disease. Cancer 1994; 74; 1720-1724.
29. Sabourin JC, Martin A, Baruch J et al. bcl-2 expression in normal breast tissue during the menstrual cycle. Int. J. Cancer 1994; 59; 1-6.
30. Lipponen P, Aaltomaa S, Kosma V-M, Syrjänen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur. J. Cancer 1994; 30A; 2068-2073.
31. Soini Y, Pääkkö P. Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Human Pathol. 1996; 27; 1221-1226.
32. Colombel M, Symmans F. Gil S et al. Detection of the apoptosissuppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am. J. Pathol. 1993; 143; 390-400.
33. Lu Q, Ella E. Lucas S et al. bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int. J. Cancer 1993; 53; 29-35.